Results 31 to 40 of about 2,105 (152)

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?

Frontiers in Oncology, 2023
Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a dismal prognosis. Enfortumab vedotin (EV) is an antibody-drug conjugate consisting of an antibody targeting Nectin-4. This protein is highly expressed in UC cells.
Brigida Anna Maiorano, Martina Catalano, Evaristo Maiello, Giandomenico Roviello   +3 more
doaj   +1 more source

Cutting‐edge advances in bicyclic peptide‐based radiotracers for cancer imaging and theranostics

VIEW, EarlyView.
Abstract Along with successful clinical approval of radiopharmaceuticals targeting somatostatin receptor subtype 2 and prostate‐specific membrane antigen, peptide‐based radiotracers have garnered the increasing attention in cancer imaging and theranostics. As a newly emerging targeting ligand in recent years, bicyclic peptides have demonstrated immense
Hengyi Ou, Xiaobo Wang, Fei Kang
wiley   +1 more source

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date

Drug Design, Development and Therapy, 2021
Mohamad Moussa,1 Athanasios Papatsoris,2 Mohamed Abou Chakra,1 Athanasios Dellis2,3 1Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon; 2 2nd Department of Urology, School of Medicine, Sismanoglio ...
Moussa M, Papatsoris A, Abou Chakra M, Dellis A   +3 more
doaj  

Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China

Cancer Medicine
Background Enfortumab vedotin, a fully human monoclonal antibody–drug conjugate (ADC) directed to Nectin‐4, prolonged overall survival (OS) versus standard chemotherapy in patients with previously treated locally advanced or metastatic urothelial ...
Siming Li, Yanxia Shi, Haiying Dong, Hongqian Guo, Yu Xie, Zhongquan Sun, Xiaoping Zhang, Eric Kim, Jun Zhang, Yue Li, Chenming Xu, Haishan Kadeerbai, Sue Lee, Seema Gorla, Jun Guo, Xinan Sheng   +15 more
doaj   +1 more source

Treatment strategies for cisplatin-ineligible metastatic bladder cancer: Emerging therapies and future perspectives [PDF]

Investigative and Clinical Urology
Recently, the combination of enfortumab vedotin and pembrolizumab has been recommended as the preferred first-line therapy for metastatic or locally advanced urothelial carcinoma owing to its substantial survival benefits.
Kyung Hwan Kim, Do Thanh Truc Phan, Hong Koo Ha, Eui Hyun Jung, Geehyun Song, Ho Kyung Seo   +5 more
doaj   +1 more source

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review

Current Urology, 2023
. Background. Bladder cancer is the 10th most common cancer globally. The majority of bladder cancers are urothelial carcinomas (UCs), which, if locally advanced or metastatic, carry poor long-term prognosis.
Maria A. Bantounou, Josip Plascevic, Lewis MacDonald, Man Chun Wong, Neasa O'Connell, Helen F. Galley   +5 more
doaj   +1 more source

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta‐analysis

BJU International, EarlyView.
Objective To evaluate the concordance between clinical complete response (cCR) and pathological complete response (pCR) in muscle‐invasive bladder cancer (MIBC) to assess the surrogacy and prognostic value of cCR for guiding bladder‐sparing strategies.
Navid Roessler, Marcin Miszczyk, Paolo Gontero, Alessandro Dematteis, Keiichiro Miyajima, Shota Inoue, Katharina Oberneder, Markus von Deimling, Victor M. Schuettfort, Malte W. Vetterlein, Bernadett Szabados, Pawel Rajwa, Pierre I. Karakiewicz, Jeremy Yuen‐Chun Teoh, Margit Fisch, Shahrokh F. Shariat   +15 more
wiley   +1 more source

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium

Journal of Hematology & Oncology, 2023
Antibody–drug conjugates (ADCs) combine the cytotoxicity of small-molecule drugs with antibody targeting. Due to their precise and powerful effect, they have become a new hotspot and an important trend in the research and development of anti-tumor ...
Jiazheng Yu, Siyu Wu, Rong Li, Yuanhong Jiang, Jianyi Zheng, Zeyu Li, Mingyang Li, Kerong Xin, Xiaojiao Guan, Shijie Li, Xiaonan Chen   +10 more
doaj   +1 more source

Optimizing Body Size‐Based Dosing Approaches for Antibody–Drug Conjugates

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 872-880, April 2026.
Optimized dosing precision of antibody–drug conjugates (ADCs) remains challenging due to narrow therapeutic indices, efficacious doses near the maximum tolerated dose, and substantial interindividual variability in exposure. Body size‐based dosing can reduce exposure variability when the allometric scaling exponent for clearance α = 1 but may over‐ or ...
Andrew B. SyBing, Diane D. Wang
wiley   +1 more source